NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38550
Issuer: Translate Bio, Inc.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 29 Hartwell Avenue
Lexington,
MASSACHUSETTS
02139
Telephone number: 857-242-3427
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-09-14ByTara PettaAVP - Securities Operations
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Telesis Bio Charts.
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Telesis Bio Charts.

Translate Bio, Inc. News

Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
Thursday 18 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
Friday 29 March 2024 (1 month ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 1 December 2023 (5 months ago) • Edgar (US Regulatory)
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 14 November 2023 (6 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 14 November 2023 (6 months ago) • Edgar (US Regulatory)

More Translate Bio, Inc. News Articles